Glenmark

Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa

Retrieved on: 
Wednesday, September 27, 2023

MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.

Key Points: 
  • MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.
  • Alessandro Della Chà, CEO of Cosmo, said, "We are very pleased to partner with Glenmark.
  • Their strong expertise in the commercialization of pharmaceutical compounds gives us great confidence in their ability to successfully market Winlevi®.
  • Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements.

Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa

Retrieved on: 
Wednesday, September 27, 2023

MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.

Key Points: 
  • MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ --  Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.
  • Alessandro Della Chà, CEO of Cosmo, said, "We are very pleased to partner with Glenmark.
  • Their strong expertise in the commercialization of pharmaceutical compounds gives us great confidence in their ability to successfully market Winlevi®.
  • Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements.

Breaking Boundaries in Communication: Highlights from Transformance Business Media's 2nd Vision & Innovation Summit 2023 on 11th August In Hyatt Centric Juhu Mumbai

Retrieved on: 
Wednesday, August 30, 2023

MUMBAI, India, Aug. 30, 2023 /PRNewswire/ -- The 2nd Corp Comm Vision & Innovation Summit & Awards 2023 concluded with resounding success, bringing together esteemed leaders and visionaries from the corporate communication landscape.

Key Points: 
  • MUMBAI, India, Aug. 30, 2023 /PRNewswire/ -- The 2nd Corp Comm Vision & Innovation Summit & Awards 2023 concluded with resounding success, bringing together esteemed leaders and visionaries from the corporate communication landscape.
  • The event, held at Hyatt Centric Juhu Mumbai on 11th August 2023, showcased impactful Keynote session, insightful discussions and Awards & Recognition for outstanding achievers in the field of corporate communication.
  • Neeraj emphasized that we're not magicians; we're professionals with skills, attitudes, and experiences that shape the corporate communication role.
  • The event concluded on a positive note, leaving participants inspired and motivated to drive innovation and excellence in the field of corporate communication.

Breaking Boundaries in Communication: Highlights from Transformance Business Media's 2nd Vision & Innovation Summit 2023 on 11th August In Hyatt Centric Juhu Mumbai

Retrieved on: 
Wednesday, August 30, 2023

MUMBAI, India, Aug. 30, 2023 /PRNewswire/ -- The 2nd Corp Comm Vision & Innovation Summit & Awards 2023 concluded with resounding success, bringing together esteemed leaders and visionaries from the corporate communication landscape.

Key Points: 
  • MUMBAI, India, Aug. 30, 2023 /PRNewswire/ -- The 2nd Corp Comm Vision & Innovation Summit & Awards 2023 concluded with resounding success, bringing together esteemed leaders and visionaries from the corporate communication landscape.
  • The event, held at Hyatt Centric Juhu Mumbai on 11th August 2023, showcased impactful Keynote session, insightful discussions and Awards & Recognition for outstanding achievers in the field of corporate communication.
  • Neeraj emphasized that we're not magicians; we're professionals with skills, attitudes, and experiences that shape the corporate communication role.
  • The event concluded on a positive note, leaving participants inspired and motivated to drive innovation and excellence in the field of corporate communication.

Brand Institute Promotes Mark Ghobry to Divisional President, Western Europe & Emerging Markets

Retrieved on: 
Wednesday, March 15, 2023

MIAMI, March 15, 2023 /PRNewswire/ -- Brand Institute, the world's #1 naming agency and the global leader in pharmaceutical and healthcare-related name development, is proud to announce the promotion of Mark Ghobry, MPharm, to the role of Divisional President, Western Europe & Emerging Markets.

Key Points: 
  • MIAMI, March 15, 2023 /PRNewswire/ -- Brand Institute, the world's #1 naming agency and the global leader in pharmaceutical and healthcare-related name development, is proud to announce the promotion of Mark Ghobry, MPharm, to the role of Divisional President, Western Europe & Emerging Markets.
  • "Whilst the UK and Nordic region continues to thrive in the pharma and biotech sectors, we have seen enormous growth in some emerging markets, like India," commented Mr. Ghobry.
  • "As Divisional President, I look forward to working with our leadership team to provide innovative and distinguished services to our clients."
  • "We're excited to have him leading the effort to bolster and expand our reach throughout Western Europe and emerging markets."

Glenmark and Cediprof Announce Exclusive Distribution Agreement in the United States for US FDA Approved Mixed Amphetamines Immediate-Release Tablets

Retrieved on: 
Thursday, March 9, 2023

MUMBAI, India and MAHWAH, N.J. and CAGUAS, Puerto Rico, March 9, 2023 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA and Cediprof, Inc. (a part of the Neolpharma Pharmaceutical Group family of companies) have entered into an exclusive supply and distribution agreement for Cediprof's FDA-approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg, the generic version of Adderall®1 Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women's Health, Inc. Glenmark expects to commence distribution of the product in the U.S. during the second half of 2023. This product has long been on FDA's shortage list.

Key Points: 
  • Commenting on the launch, Brendan O'Grady, Chief Executive Officer – Glenmark Global Formulations Business said, "Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is a highly prescribed medication in the United States.
  • Glenmark is very pleased to be able to alleviate the shortage this country is facing by partnering with Cediprof and Neol."
  • According to IQVIA™ sales data for the 12-month period ending January 2023, the Adderall® Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market2 achieved annual sales of approximately $389.8 million*.
  • Glenmark's current portfolio consists of 180 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the U.S. FDA.

Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials

Retrieved on: 
Tuesday, January 10, 2023

MAHWAH, N.J., Jan. 10, 2023 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex®1 Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.

Key Points: 
  • MAHWAH, N.J., Jan. 10, 2023 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex®1 Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.
  • Commenting on the launch, Vijay Raghavan, Senior Vice President, Business Development Portfolio, Product Launch & Strategy, said, "We are very pleased to bring to market a lower cost alternative to Bumex® Injection, 0.25 mg/mL.
  • This launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials affirms our commitment to Glenmark's continued focus on institutional business."
  • According to IQVIATM sales data for the 12-month period ending November 2022, the Bumex® Injection, 0.25 mg/mL market2 achieved annual sales of approximately $16.5 million*.

Glenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US

Retrieved on: 
Monday, October 31, 2022

MUMBAI, India and MAHWAH, N.J., Oct. 31, 2022 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched their Fingolimod Capsules, 0.5 mg, the generic version of Gilenya1 Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.

Key Points: 
  • MUMBAI, India and MAHWAH, N.J., Oct. 31, 2022 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched their Fingolimod Capsules, 0.5 mg, the generic version of Gilenya1 Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.
  • Commenting on the launch, Sanjeev Krishan, President, Glenmark North America said, "We are very pleased to bring to market a lower cost alternative to GilenyaCapsules, 0.5 mg.
  • According to IQVIAsales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market2 achieved annual sales of approximately $1.8 billion*.
  • Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is an innovationdriven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses.

Glenmark Pharmaceuticals Inc., USA continues to expand its Over-The-Counter (OTC) Portfolio with the acquisition of approved ANDAs from Wockhardt Limited

Retrieved on: 
Tuesday, June 28, 2022

Glenmark's current portfolio consists of 175 products authorized for distribution in the U.S. marketplace and 48 ANDAs pending approval with the U.S. FDA.

Key Points: 
  • Glenmark's current portfolio consists of 175 products authorized for distribution in the U.S. marketplace and 48 ANDAs pending approval with the U.S. FDA.
  • In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
  • Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses.
  • The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries.

Glenmark inks agreement with AstraZeneca to commercialize its product Pulmicort Respules® in Colombia

Retrieved on: 
Monday, February 14, 2022

BOGOTA, Colombia, Feb. 14, 2022 /PRNewswire/ -- Glenmark Pharmaceuticals, an innovation–driven, global pharmaceutical company, today announced that its subsidiary Glenmark Pharmaceuticals Colombia S.A.S. and AstraZeneca Colombia S.A.S. have entered into an exclusive licensing agreement for the commercialization of AstraZeneca's drug Pulmicort Respules®. Under the terms of the agreement, AstraZeneca remains the holder of the registration for Pulmicort Respules® and will be responsible for manufacturing and supplying the drug. Glenmark will be responsible for commercialization of Pulmicort Respules® in the Colombian market.

Key Points: 
  • - As per this agreement, AstraZeneca remains the holder of the registration for Pulmicort Respules and will manufacture the drug.
  • Glenmark will commercialize the product in Colombia.
  • have entered into an exclusive licensing agreement for the commercialization of AstraZeneca's drug Pulmicort Respules.
  • Under the terms of the agreement, AstraZeneca remains the holder of the registration for Pulmicort Respules and will be responsible for manufacturing and supplying the drug.